



ASO Visual Abstract: The Prognostic Role of the Number of Involved Structures in Thymic Epithelial Tumors: Results from the ESTS Database

Marco Chiappetta, MD^{1,2}, Filippo Lococo, MD^{1,2}, Carolina Sassorossi, MD^{1,2}, Clemens Aigner, MD³, Till Ploenes, MD^{4,5,6,7,8,9}, Dirk Van Raemdonck, MD¹⁰, Cedric Vanluyten, MD¹⁰, Paul Van Schil, MD¹¹, Apostolos Agrafiotis, MD¹¹, Francesco Guerrera, MD¹², Paraskevas Lyberis, MD¹², Monica Casiraghi, MD^{13,14}, Lorenzo Spaggiari, MD^{13,14}, Charalambos Zisis, MD¹⁵, Christina Magou, MD¹⁵, Bernhard Moser, MD¹⁶, Jonas Bauer, MD¹⁶, Pascal Alexandre Thomas, MD¹⁷, Geoffrey Brioude, MD¹⁷, Stefano Passani, MD¹⁸, Zalan Zsanto, MD¹⁹, Isabella Sperduti, MD²⁰, and Stefano Margaritora, MD^{1,2}

¹Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; ²Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; ³Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; ⁴Division of Thoracic Surgery, Department of Visceral, Thoracic and Vascular Surgery, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; ⁵National Center for Tumor Diseases (NCT/UCC), TU Dresden, Dresden, Sachsen, Germany; ⁶German Cancer Research Center (DKFZ), Heidelberg, Germany; ⁷Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; ⁸Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany; ⁹Department of Thoracic Surgery, Fachkrankenhaus Coswig GmbH, Coswig, Saxony, Germany; ¹⁰Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium; ¹¹Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium; ¹²Department of Surgical Sciences, Thoracic Surgery Unit, University of Turin, Torino, Italy; ¹³Division of Thoracic Surgery, IEO, Istituto Europeo di Oncologia, IRCCS, Milan, Italy; ¹⁴Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy; ¹⁵Department of Thoracic Surgery, Evangelismos Hospital, Athens, Greece; ¹⁶Head, ESTS Thymic Working Group, Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; ¹⁷Department of Thoracic Surgery, North Hospital, APHM and Aix-Marseille University, Marseille, France; ¹⁸Managing Director KData Clinical srl, Rome, Italy; ¹⁹Department of Surgery Medical School, University of Pécs, Pécs, Hungary; ²⁰Biostatistics, Regina Elena National Cancer Institute – IRCCS, Rome, Italy

Thymic epithelial tumors (TETs) often present multiple structure infiltration. The number of involved structures (NIS) is an independent predictor of CSS. Patients with NIS

≤ 2 presented a significantly better CSS than patients with NIS > 2 (<https://doi.org/10.1245/s10434-024-15194-z>).

The abstract of this work was presented at the 59th STS Meeting, San Diego, CA, USA, 13–23 January 2023.

© Society of Surgical Oncology 2024, corrected publication 2024


Published online: 7 May 2024

M. Chiappetta, MD
e-mail: marco.chiappetta@policlinicogemelli.it;
marcokiaps@hotmail.it

The Prognostic Role of the Number of Involved Structures in Thymic Epithelial Tumours: Results From the ESTS Database

The prognostic role of the number of involved structures (NIS) in Thymic Epithelial Tumours is not well evaluated among the Masaoka-Koga and the TNM staging System.

We reviewed the European Society of Thoracic Surgeons database with the aim to investigate if the prognosis may change according to this factor.



	5Y CSS	10Y CSS
NIS ≤ 2	93.2%	91.2%
NIS > 2	89.5%	83.5%



Multivariable analysis for Cancer Specific Survival

CANCER SPECIFIC SURVIVAL		
Variable	P value	HR,95%CI
Myasthenia Gravis No vs yes	0.109	4.27 [0.72; 25.17]
Histology Carcinoma/NET vs Thymoma	0.053	3.32 [0.98; 11.20]
Pathological resection status R+ vs R0	0.048	2.54 [1.01; 6.40]
Number of involved structures >2 vs ≤2	0.036	1.39 [1.02; 1.90]

Number of involved structures is an independent prognostic factor in advanced thymic epithelial tumors

Chiappetta et al. *Ann Surg Oncol*.

Visual Abstract by @Marco.chiappetta for @AnnSurgOncol

ANNALS OF
**SURGICAL
ONCOLOGY**

FUNDING No sources of funding were received to assist in the preparation of this work.

DATA AVAILABILITY Data are managed by the European Society of Thoracic Surgeons (ESTS) databases committee and are available according to ESTS database regulation.

DISCLOSURES Paul Van Schil has been a member of advisory boards and received honoraria (personal and institutional) for lectures from AstraZeneca, BMS, MSD, Janssen and Roche. Pascal A. Thomas undertakes consultancy work and is a scientific board member for Roche, AstraZeneca, BMS, and Amgen. Marco Chiappetta, Filippo Lococo, Carolina Sassorossi, Clemens Aigner, Till Ploenes, Dirk

Van Raemdonck, Cedric Vanluyten, Apostolos Agrafiotis, Francesco Guerrero, Paraskevas Lyberis, Monica Casiraghi, Lorenzo Spaggiari,, Charalambos Zisis, Christina Magou, Bernhard Moser, Jonas Bauer, Geoffrey Brioude, Stefano Passani, Zalan Zsanto, Isabella Sperduti, and Stefano Margaritora have no disclosures to declare in relation to this work.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.